Alkermes plc. (ALKS): Free Cash Flow
$480.33M
Year ended 2025-12-31
$221.65M
Trailing 12 months to 2026-06-30
+63.9%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $480.33M | +18.4% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $405.64M | +14.8% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $353.31M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$17.21M | n/m | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $73.69M | +81.4% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $40.62M | n/m | 2023-02-16, From 2020-01-01 |
| 2019-12-31 | -$18.86M | n/m | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $29.85M | n/m | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | -$32.11M | n/m | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | -$107.46M | n/m | 2019-02-15, From 2016-01-01 |
| 2015-12-31 | -$93.24M | n/m | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | -$22.51M | n/a | 2017-02-17, From 2014-01-01 |
| No annual figure between 2012-03-31 and 2014-12-31. | |||
| 2012-03-31 | -$19.47M | n/m | 2013-05-23, From 2011-04-01 |
| 2011-03-31 | -$15.31M | n/m | 2013-05-23, From 2010-04-01 |
| 2010-03-31 | -$28.03M | n/a | 2012-05-18, From 2009-04-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Alkermes plc. (ALKS) | 2025-12-31 | $480.33M | +18.4% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $9.87M | -76.4% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $702.34M | n/m |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | -$93.00M | n/m |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $246.45M | +1.3% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $105.15M | -33.1% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$307.45M | n/m |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$190.02M | n/m |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | -$320.03M | n/m |
Compare ALKS, PAHC, PTCT, INDV side by side · Screen every company in Pharmaceutical Preparations ↗